Table 5.
Results of meta-analysis
| Groups |
Diagnosis |
N staging |
Liver metastasis |
Prognosis |
||||
| Sen (95%CI) | Spe (95%CI) | Sen (95%CI) | Spe (95%CI) | Pv- (95%CI) | Sen (95%CI) | Spe (95%CI) | HR (95%CI) | |
| Overall | 0.91 (0.88-0.93) | 0.81 (0.75-0.85) | 0.64 (0.50-0.76) | 0.81 (0.25-0.85) | 0.65 (0.28-0.90) | 0.67 (0.52-0.79) | 0.96 (0.89-0.98) | |
| P subgroup | 0.89 (0.84-0.92) | 0.84 (0.76-0.89) | 0.56 (0.15-0.90) | 0.79 (0.48-0.94) | - | 0.57 (0.21-0.88) | 0.94 (0.68-0.99) | 2.39 (1.57-3.63) |
| R subgroup | 0.90 (0.83-0.95) | 0.75 (0.58-0.87) | 0.61 (0.32-0.85) | 0.17 (0.04-0.81) | - | 0.56 (0.28-0.81) | 0.94 (0.65-0.99) | 3.40 (2.01-5.74) |
| NR subgroup | 0.93 (0.88-0.96) | 0.82 (0.74-0.87) | 0.70 (0.46-0.87) | 0.97 (0.84-0.99) | - | 0.74 (0.52-0.88) | 0.92 (0.83-0.96) | 3.96 (1.92-8.17) |
| PET subgroup | 0.91 (0.88-0.93) | 0.80 (0.74-0.85) | - | - | - | 0.67 (0.52-0.79) | 0.96 (0.89-0.98) | 2.06 (1.26-3.36) |
| PET/CT subgroup | 0.90 (0.79-0.95) | 0.85 (0.38-0.98) | - | - | - | 0.82 (0.48-0.98) | 0.97 (0.87-1.00) | - |
N: Lymph node; P: Prospective; R: Retrospective; NR: Not reporting; Sen: Sensitivity; Spe: Specificity; Pv-: Negative predictive value; PET: Positron emission tomography; CT: Computed tomography.